Pharmacotherapies for sleep disturbances in dementia
McCleery J, et al.
Published in Cochrane Database of Systematic Reviews
Methodology
Cochrane systematic review of randomized controlled trials of drug treatments for sleep disturbance in people with dementia, with actigraphy-based and clinician-rated sleep outcomes and adverse events.
Key Findings
No difference was found between melatonin and placebo for sleep efficiency, time awake after sleep onset, or number of night-time awakenings in people with dementia; trazodone showed some benefit on total night-time sleep in a single small trial, and evidence for other agents was insufficient.
Conclusions
From single studies, we found no difference between melatonin and placebo groups for sleep efficiency, time awake after sleep onset, or number of night-time awakenings.
Limitations
Very few eligible trials, each small and mostly single studies per drug, short follow-up, and low-certainty evidence overall precluding pooled conclusions.
Supplements Studied
From single studies, we found no difference between melatonin and placebo groups for sleep efficiency, time awake after sleep onset, or number of night-time awakenings.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Cochrane Dementia and Cognitive Improvement Group; no commercial sponsorship reported.
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.